Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4363 - The combination of MEK inhibitor and anti PD-L1: effects on organoid models from NSCLC biopsies

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Carminia Maria Della Corte

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

C.M. Della Corte1, G. Barra2, V. Ciaramella3, R. Di Liello3, M. Fasano4, F. Ciardiello4, F. Morgillo4

Author affiliations

  • 1 Thoracic Head And Neck, MD ANDERSON CANCER CENTER, 77030 - HOUSTON/US
  • 2 Immunologia, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 80138 - Napoli/IT
  • 3 Precision Medicine, Università degli studi della campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 4 Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
More

Resources

Abstract 4363

Background

The combination of immune-checkpoint (IC) inhibitors with targeted therapies represent a new goal of immunotherapy, aimed at personalizing and potentiating the self-response against cancer. Organoids as novel 3D cancer models, allow the study in vitro of the tumor microenvironment (TME), including tumor-infiltrating lymphocytes (TILs) and their interaction with tumor cells. In this study we analyzed whether the combination of anti-PD-L1 drugs with MEK inhibitor (MEKi) affect the growth of organoids and TILs obtained from tumor biopsy of NSCLC patients.

Methods

Lung biopsies from 3 NSCLC patients were enzymatically digested. Cells were cultured in matrigel for 6 days and treated with atezolizumab or avelumab, alone or in combination with MEKi. Immunofluorescence (IF) staining for CD3, CD8 and CD45 was conducted; cells were also stained for FACS analysis with anti- CD45, CD3, CD4, CD8, CD14, CD56, CD19, CD11c, PD-1; a staining for EPCAM and PD-L1 allowed a better characterization of tumor cells. After 6 days of treatment, MTT assay verified cell viability; the expression levels of IFNg, IL-10, PD-1, PD-L1, TIM-3, LAG-3 and IDO-1 were analysed through real-time PCR.

Results

IF staining revealed that in organoids the interactions between tumor cells and TILs are preserved. FACS analysis confirmed that TILs were mainly TCD8+ and tumor cells analysed were EPCAM+ for almost 40%. The combination of anti PD-L1 and MEKi is associated with a reduction in organoid’s dimensions and viability, especially in PD-L1+ tumors and with a higher percentage of TCD8+/PD-1+ lymphocytes. The combination of MEKi with anti PD-L1 is also associated to a higher expression of the pro-inflammatory cytokine IFNg and a reduction of the anti-inflammatory IL10. The expression of IC molecules was also modified by this combination; in particular LAG-3 and IDO-1 expression were dramatically reduced.

Conclusions

Organoid models allow to study tumors more realistically, because they show some typical features of the organ they derive. This model become particularly useful for the analysis of TME of each patient and for the testing of combination drugs and the development of precision and personalized immunotherapies.

Clinical trial identification

Legal entity responsible for the study

Università degli Studi della Campania.

Funding

AIRC.

Editorial Acknowledgement

NA

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings